2024
Using a Bayesian analytic approach to identify county-level ecological factors associated with survival among individuals with early-onset colorectal cancer
Siddique S, Baum L, Deziel N, Kelly J, Warren J, Ma X. Using a Bayesian analytic approach to identify county-level ecological factors associated with survival among individuals with early-onset colorectal cancer. PLOS ONE 2024, 19: e0311540. PMID: 39471191, PMCID: PMC11521299, DOI: 10.1371/journal.pone.0311540.Peer-Reviewed Original ResearchConceptsAge-of-onset colorectal cancerEarly-onset colorectal cancerEnd Results Program dataCenters for Disease Control and Prevention dataCounty-level factorsColorectal cancerHealth risk behaviorsIdentified principal componentsOdds of survivalPreventive servicesSurvival disparitiesLinear mixed modelsEOCRCChronic diseasesPreventive factorsUS countiesSalt Lake CountyCA residentsRisk behaviorsUnited StatesProgram dataCounty-levelOlder ageBayesian analytical approachYounger age
2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOS
2016
Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394. DOI: 10.1182/blood.v128.22.394.394.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaMyelodysplastic syndromeSurvival benefitHigh-risk myelodysplastic syndromeDemonstrated survival benefitRetrospective cohort studyRisk myelodysplastic syndromesUse of HMAsAgent azacitidineLack of evidenceCohort studyClinical entityMyelomonocytic leukemiaBiologic evidenceOlder adultsAzacitidineUnited StatesHMAsEnd resultPatientsSyndromeLeukemiaDecitabineEpidemiology
2012
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research 2012, 36: 1370-1375. PMID: 22917770, PMCID: PMC3458648, DOI: 10.1016/j.leukres.2012.07.020.Peer-Reviewed Original ResearchConceptsCost of careMyelodysplastic syndromeMDS patientsMedicare expendituresComparative cost-effectiveness studyCohort of patientsTwo-year survivalNon-cancer controlsCost-effectiveness studiesElderly patientsPrevalent cancerEconomic burdenPatientsMajor subtypesSurvivalCareSyndromeUnited StatesHMAsSurvival probabilityEarly periodCohortAgentsCancerSubtypes
2008
Prevalence of polycythemia vera and essential thrombocythemia
Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. American Journal Of Hematology 2008, 83: 359-362. PMID: 18181200, DOI: 10.1002/ajh.21129.Peer-Reviewed Original ResearchConceptsPrevalence of PVPolycythemia veraEssential thrombocythemiaMyeloproliferative disordersUS populationAge-standardized prevalenceHealth claims dataAge-specific prevalenceLarge US populationEntire US populationClaims dataET patientsInsurance payerHealth claimsLogistic regressionPrevalencePatientsMedicaid ServicesMolecular etiologyCommon typeThrombocythemiaDisordersUnited StatesAffected populationVera